NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel...
null
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel...
null
NeuroSense Announces Pricing of Insider-Led PIPE Financing
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel...
null
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
null
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...
null
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
null
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
null
/C O R R E C T I O N -- NeuroSense/
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
null
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
null
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
#Product Stage
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
#Product Stage
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
#Product Stage
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
null
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage #FDA approved/pending approval
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage #Management Changes
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
#Product Stage #Management Changes
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
#Product Stage
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
undefined
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
#Product Stage
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
#Product Stage #FDA approved/pending approval
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage #FDA approved/pending approval
NeuroSense to Host Investor Webinar on December 8, 2025
#Product Stage #Investment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage #Investment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
#Product Stage
Sector Update: Health Care Stocks Retreat Late Afternoon
undefined
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage #Partners
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
#Product Stage
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
#Investment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
#Product Stage #Investment #Partners
NeuroSense Provides Business Update and Progress for the First Half of 2025
#Product Stage #Investment #Partners
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
#Product Stage #Partners
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Product Stage #Partners
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
#Product Stage #Partners #Customers
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
#Product Stage #Partners
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
#Product Stage #Partners
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
#Product Stage #Partners #FDA approved/pending approval
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
#Product Stage
/PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe...
#Product Stage
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
#Product Stage #Partners
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
#Product Stage
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
#Product Stage #Partners
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
#Product Stage #Partners
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
#Product Stage #Investment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Partners
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
#Partners
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
#Investment
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
undefined
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
undefined
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Investment
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
#Investment
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
undefined
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
undefined
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
#Partners
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
undefined
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
undefined
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
#Expand
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
undefined
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
undefined
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
undefined
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
#Public Trading #Partners
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
#Investment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
#Investment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel...
#Public Trading
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
#Public Trading
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
#Partners
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
#Investment #Management Changes
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
#Investment #Partners
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
#Investment, Partners
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
#Investment #Expand
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
#Investment
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
#Public Trading
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
#Management Changes
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
#Partners #Expand
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
#Investment
NeuroSense Announces First Quarter 2024 Business Update
#Partners #Expand
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
#Partners
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
#Investment
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
#Investment
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
#Investment
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
#Partners
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
#Investment
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
#Investment
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
#Public Trading
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
#Investment #Partners
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
#Partners #Expand
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
#Public Trading
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
#Investment
We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
#Investment
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
#Investment #Partners
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
#Investment
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
#Investment #Partners
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
#Investment #Expand
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
#Investment, Management Changes
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
#Customers #Partners
NeuroSense Therapeutics to Participate in BIO-Europe Fall
#Partners
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
undefined
NeuroSense CEO Provides Q3 2023 Update
undefined
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
#Investment
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
#Partners
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
#Partners
European Medicines Agency Grants NeuroSense SME Status
#Expand
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
#Investment
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
#Customers, Expand
NeuroSense to Host Investor Webinar on September 12, 2023
#Investment
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
#Investment #Partners
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
#Investment #Partners
NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
#Partners #Expand
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
#Investment
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
#Investment #Partners #Expand
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
#Customers
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
#Customers
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
#Customers #Partners
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
#Partners
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
#Investment #Expand
NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
#Investment #Partners #Management Changes
NeuroSense Therapeutics to Participate in BIO-Europe Spring
#Partners
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
#Investment
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
undefined
Here's Why We're Watching NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Situation
undefined
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
undefined
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
#Customers
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
#Customers
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
#Investment
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
undefined
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
#Customers #Partners
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
undefined
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
#Partners #Expand
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
#Partners
NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI CTech
undefined
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
#Customers
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS BioSpace
#Customers
NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia
#Customers
NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market
#Public Trading
NeuroSense Therapeutics Publicly Files Registration Statement with SEC for Proposed U.S. Initial Public Offering
#Public Trading
נוירוסנס הישראלית תנפיק בנאסד"ק כדי להיאבק באחת המחלות הקטלניות ביותר
#Public Trading #Investment
נוירוסנס תרפיוטיקס באתגר דלי הקרח: גיוס מקדים לפי שווי 80 מיליון דולר
#Investment #Public Trading
Hillel's Tech Corner: NeuroSense: What ALS patients deserve
undefined
NeuroSense Therapeutics Announces Continuation of Positive Trends in Clinical Study in ALS
#Customers
PrimeC Shows Potential to Slow ALS Progression, Interim Data Reveal
#Investment #Expand
NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS
#Investment
NeuroSense Therapeutics Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis (ALS) Drug, and Announces Initiation of Two Clinical Studies in ALS BioSpace
#Customers
ALS Drug Developer NeuroSense Crowdfunds $1.15 Million
#Investment
"You're an entrepreneur, if ALS has no cure, find one"
#Investment
https://www.jpost.com/HEALTH-SCIENCE/Meet-the-Israeli-company-optimistic-about-beating-ALS-580232?fbclid=IwAR0Sz2xC_z3nGUkcyNkYF8V6YQlDHvP2sEVuQmTJ6oEqLjq6HO5ST19XVZE
#Customers #Investment
NeuroSense to develop ALS treatment
#Investment